Tesofensine is currently in phase 3 clinical trials with the FDA and supported by further research at Johns Hopkins University School of Medicine. This peptide is the mildest growth hormone-releasing peptide and also the most versatile one. It is said to be the most suitable peptide as it doesn’t induce Continue Reading